Quest Diagnostics Incorporated has announced that it will offer a new FDA-cleared blood test for Alzheimer's disease, developed by Fujirebio. This test, based on the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio, is the first blood-based in-vitro diagnostic test cleared by the U.S. Food and Drug Administration to help identify patients with amyloid pathology associated with Alzheimer's disease. Quest Diagnostics plans to make this test available for both clinical and research use later this summer, offering a less invasive and more convenient option compared to traditional methods. The test is designed for adult patients aged 50 and older who are showing signs of cognitive decline, and it expands Quest's existing AD-Detect™ product line for assessing symptomatic patients.